Chinese Journal of Antituberculosis ›› 2026, Vol. 48 ›› Issue (9): 1364-1374.doi: 10.19982/j.issn.1000-6621.20260223
• Original Articles • Previous Articles Next Articles
Zhou Ran1, Deng Jing1(
), Chen Haiyi1, Zhang Ting2, Zheng Denghu3
Received:2026-04-20
Online:2026-09-10
Published:2026-09-08
Contact:
Deng Jing
E-mail:cqmudj@cqmu.edu.cn
Supported by:CLC Number:
Zhou Ran, Deng Jing, Chen Haiyi, Zhang Ting, Zheng Denghu. Risk prediction of catastrophic household cost among patients with rifampicin-susceptible pulmonary tuberculosis in Chongqing Municipality[J]. Chinese Journal of Antituberculosis, 2026, 48(9): 1364-1374. doi: 10.19982/j.issn.1000-6621.20260223
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20260223
| 特征 | 合计(355例) | 训练集(249例) | 验证集(106例) | χ2值 | P值 | ||||
|---|---|---|---|---|---|---|---|---|---|
| 性别 | 0.092 | 0.761 | |||||||
| 男性 | 259(72.96) | 180(72.29) | 79(74.53) | ||||||
| 女性 | 96(27.04) | 69(27.71) | 27(25.47) | ||||||
| 年龄组(岁) | 5.323 | 0.070 | |||||||
| <25 | 40(11.27) | 25(10.04) | 15(14.15) | ||||||
| 25~44 | 73(20.56) | 45(18.07) | 28(26.42) | ||||||
| ≥45 | 242(68.17) | 179(71.89) | 63(59.43) | ||||||
| 户籍所在地 | 0.848 | 0.654 | |||||||
| 本县区 | 317(89.30) | 221(88.76) | 96(90.57) | ||||||
| 本省非本县区 | 31(8.73) | 22(8.84) | 9(8.49) | ||||||
| 外省 | 7(1.97) | 6(2.40) | 1(0.94) | ||||||
| 受教育程度 | 2.974 | 0.396 | |||||||
| 小学及以下 | 160(45.07) | 116(46.59) | 44(41.51) | ||||||
| 初中 | 106(29.86) | 77(30.92) | 29(27.36) | ||||||
| 高中及同等学历 | 52(14.65) | 33(13.25) | 19(17.92) | ||||||
| 大专及以上 | 37(10.42) | 23(9.24) | 14(13.21) | ||||||
| 职业 | 1.307 | 0.860 | |||||||
| 企事业单位/职工 | 87(24.51) | 62(24.90) | 25(23.58) | ||||||
| 农民 | 94(26.48) | 65(26.10) | 29(27.36) | ||||||
| 学生 | 32(9.01) | 20(8.03) | 12(11.32) | ||||||
| 无业 | 85(23.94) | 62(24.90) | 23(21.70) | ||||||
| 其他 | 57(16.06) | 40(16.07) | 17(16.04) | ||||||
| 重点人群 | 0.004 | 0.949 | |||||||
| 否 | 247(69.58) | 174(69.88) | 73(68.87) | ||||||
| 是 | 108(30.42) | 75(30.12) | 33(31.13) | ||||||
| 患者类型 | 0.793 | 0.373 | |||||||
| 初治 | 330(92.96) | 229(91.97) | 101(95.28) | ||||||
| 复治 | 25(7.04) | 20(8.03) | 5(4.72) | ||||||
| 治疗方案 | 1.209 | 0.272 | |||||||
| 标准治疗方案(2H-R-Z-E/4H-R) | 257(72.39) | 185(74.30) | 72(67.92) | ||||||
| 非标准治疗方案 | 98(27.61) | 64(25.70) | 34(32.08) | ||||||
| 住院情况 | 0.362 | 0.547 | |||||||
| 否 | 101(28.45) | 68(27.31) | 33(31.13) | ||||||
| 是 | 254(71.55) | 181(72.69) | 73(68.87) | ||||||
| 家庭年收入(元) | 1.624 | 0.444 | |||||||
| <50000 | 139(39.15) | 96(38.56) | 43(40.57) | ||||||
| 50000~100000 | 163(45.92) | 119(47.79) | 44(41.51) | ||||||
| >100000 | 53(14.93) | 34(13.65) | 19(17.92) | ||||||
| 陪护情况 | 0.049 | 0.825 | |||||||
| 无 | 277(78.03) | 193(77.51) | 84(79.25) | ||||||
| 有 | 78(21.97) | 56(22.49) | 22(20.75) | ||||||
| 医保类型 | 0.280 | 0.869 | |||||||
| 城镇居民医保 | 277(78.03) | 194(77.91) | 83(78.30) | ||||||
| 城镇职工医保 | 70(19.72) | 50(20.08) | 20(18.87) | ||||||
| 其他 | 8(2.25) | 5(2.01) | 3(2.83) | ||||||
| 职业变动 | <0.001 | 1.000 | |||||||
| 否 | 258(72.68) | 181(72.69) | 77(72.64) | ||||||
| 是 | 97(27.32) | 68(27.31) | 29(27.36) | ||||||
| 家庭主要收入来源者 | 0.035 | 0.851 | |||||||
| 否 | 210(59.15) | 146(58.63) | 64(60.38) | ||||||
| 是 | 145(40.85) | 103(41.37) | 42(39.62) | ||||||
| 合并慢性病 | <0.001 | 1.000 | |||||||
| 否 | 247(69.58) | 173(69.48) | 74(69.81) | ||||||
| 是 | 108(30.42) | 76(30.52) | 32(30.19) | ||||||
| 发生灾难性支出 | 0.009 | 0.926 | |||||||
| 否 | 147(41.41) | 104(41.77) | 43(40.57) | ||||||
| 是 | 208(58.59) | 145(58.23) | 63(59.43) | ||||||
| 特征 | 合计(例) | 发生例数 | 发生率(%) | χ2值 | P值 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 性别 | 3.149 | 0.076 | ||||||||
| 男性 | 180 | 111 | 61.67 | |||||||
| 女性 | 69 | 34 | 49.28 | |||||||
| 年龄组(岁) | 18.836a | <0.001 | ||||||||
| <25 | 25 | 8 | 32.00 | |||||||
| 25~44 | 45 | 17 | 37.78 | |||||||
| ≥45 | 179 | 120 | 67.04 | |||||||
| 户籍所在地 | - | 0.036 | ||||||||
| 本县区 | 221 | 134 | 60.63 | |||||||
| 本省非本县区 | 22 | 10 | 45.45 | |||||||
| 外省 | 6 | 1 | 16.67 | |||||||
| 受教育程度 | 9.604a | 0.002 | ||||||||
| 小学及以下 | 116 | 78 | 67.24 | |||||||
| 初中 | 77 | 45 | 58.44 | |||||||
| 高中及同等学历 | 33 | 11 | 33.33 | |||||||
| 大专及以上 | 23 | 11 | 47.83 | |||||||
| 职业 | 20.409 | <0.001 | ||||||||
| 企事业单位/职工 | 62 | 45 | 72.58 | |||||||
| 农民 | 65 | 38 | 58.46 | |||||||
| 学生 | 20 | 4 | 20.00 | |||||||
| 无业 | 62 | 31 | 50.00 | |||||||
| 其他 | 40 | 27 | 67.50 | |||||||
| 重点人群 | 0.008 | 0.927 | ||||||||
| 否 | 174 | 101 | 58.05 | |||||||
| 是 | 75 | 44 | 58.67 | |||||||
| 患者类型 | 0.409 | 0.522 | ||||||||
| 初治 | 229 | 132 | 57.64 | |||||||
| 复治 | 20 | 13 | 65.00 | |||||||
| 治疗方案 | 1.935 | 0.164 | ||||||||
| 标准治疗方案(2H-R-Z-E/4H-R) | 185 | 103 | 55.68 | |||||||
| 非标准治疗方案 | 64 | 42 | 65.62 | |||||||
| 住院情况 | 31.948 | <0.001 | ||||||||
| 否 | 68 | 20 | 29.41 | |||||||
| 是 | 181 | 125 | 69.06 | |||||||
| 家庭年收入(元) | 36.510a | <0.001 | ||||||||
| <50000 | 96 | 78 | 81.25 | |||||||
| 50000~100000 | 119 | 57 | 47.90 | |||||||
| >100000 | 34 | 10 | 29.41 | |||||||
| 陪护情况 | 0.183 | 0.669 | ||||||||
| 无 | 193 | 111 | 57.51 | |||||||
| 有 | 56 | 34 | 60.71 | |||||||
| 医保类型 | - | 1.000 | ||||||||
| 城乡居民医保 | 194 | 113 | 58.25 | |||||||
| 城镇职工医保 | 50 | 29 | 58.00 | |||||||
| 其他 | 5 | 3 | 60.00 | |||||||
| 职业变动 | 31.310 | <0.001 | ||||||||
| 否 | 181 | 86 | 47.51 | |||||||
| 是 | 68 | 59 | 86.76 | |||||||
| 家庭主要收入来源者 | 15.359 | <0.001 | ||||||||
| 否 | 146 | 70 | 47.95 | |||||||
| 是 | 103 | 75 | 72.82 | |||||||
| 合并慢性病 | 24.513 | <0.001 | ||||||||
| 否 | 173 | 83 | 47.98 | |||||||
| 是 | 76 | 62 | 81.58 | |||||||
| 变量 | β值 | s | Wald χ2值 | P值 | OR值 | 95%CI值 |
|---|---|---|---|---|---|---|
| 常数 | -0.571 | 0.397 | 2.077 | 0.150 | 0.565 | 0.255~1.220 |
| 住院 | 1.776 | 0.400 | 19.755 | <0.001 | 5.906 | 2.752~13.279 |
| 家庭年收入(以<50000元为对照) | ||||||
| 家庭年收入为50000~100000元 | -1.977 | 0.408 | 23.449 | <0.001 | 0.138 | 0.060~0.300 |
| 家庭年收入>100000元 | -3.357 | 0.612 | 30.074 | <0.001 | 0.035 | 0.010~0.109 |
| 职业变动 | 2.491 | 0.490 | 25.854 | <0.001 | 12.074 | 4.844~33.425 |
| 家庭主要收入来源者 | 0.870 | 0.367 | 5.622 | 0.018 | 2.388 | 1.174~4.985 |
| 合并慢性病 | 1.195 | 0.417 | 8.204 | 0.004 | 3.304 | 1.485~7.686 |
| [1] |
Floyd K, Glaziou P, Houben R M G J, et al. Global tuberculosis targets and milestones set for 2016-2035: definition and rationale[J]. Int J Tuberc Lung Dis, 2018, 22(7): 723-730. doi:10.5588/ijtld.17.0835.
pmid: 29914597 |
| [2] | World Health Organization. Global tuberculosis report 2025[R]. Geneva: World Health Organization, 2025. |
| [3] | 杨天池, 陈琴, 陈同, 等. 宁波市利福平耐药肺结核患者家庭灾难性医疗支出及其影响因素分析[J]. 中国防痨杂志, 2019, 41(11): 1191-1196. doi:10.3969/j.issn.1000-6621.2019.11.009. |
| [4] | 王佳妮, 席明霞. 结核病灾难性卫生支出的研究进展[J]. 中国防痨杂志, 2024, 46(1): 112-118. doi:10.19982/j.issn.1000-6621.20230345. |
| [5] | 王倩, 张修磊, 阴佳. 山东省耐多药肺结核患者医疗费用灾难性支出分析研究[J]. 河南预防医学杂志, 2020, 31(12): 918-920. doi:10.13515/j.cnki.hnjpm.1006-8414.2020.12.013. |
| [6] | He F, Wang S, Wang H, et al. Development and validation of a nomogram predictingmultidrug-resistant tuberculosis risk in East China[J]. PeerJ, 2025, 1: e19112. doi:10.7717/peerj.19112. |
| [7] | 张莹, 张志苏, 施自伦, 等. 基于CD161构建肺结核的临床诊断模型[J]. 安徽医科大学学报, 2025, 60(3): 515-523. doi:10.19405/j.cnki.issn1000-1492.2025.03.018. |
| [8] | 阮淑金, 陈敬芳, 王秀芬, 等. 肺结核患者治疗不依从影响因素分析及风险预测模型的构建研究[J]. 结核与肺部疾病杂志, 2025, 6(2): 183-190. doi:10.19983/j.issn.2096-8493.20250021. |
| [9] | 王帅, 全薇, 罗勇军. 重庆市“一区两群”空间分布格局下医疗卫生资源配置公平性评价及预测[J]. 现代预防医学, 2023, 50(18): 3352-3357,3446. doi:10.20043/j.cnki.MPM.202304106. |
| [10] | 王前, 李涛, 杜昕, 等. 2015-2019年全国肺结核报告发病情况分析[J]. 中国防痨杂志, 2021, 43(2):107-112. doi:10.3969/j.issn.1000-6621.2021.02.002. |
| [11] | 吴波, 刘英, 廖文平, 等. 重庆市四区县肺结核患者经济负担分析[J]. 中国防痨杂志, 2022, 44(4): 390-396. doi:10.19982/j.issn.1000-6621.20210633. |
| [12] | 郝冬青, 李涛, 黄飞, 等. 我国西部地区肺结核患者家庭经济负担现况调查[J]. 中国防痨杂志, 2023, 45(11): 1021-1030. doi:10.19982/j.issn.1000-6621.20230137. |
| [13] | 张亚宁, 杨培荣, 严钏元, 等. 陕西省宝鸡市肺结核患者家庭灾难性支出预测模型构建与验证[J]. 中国防痨杂志, 2025, 47(9): 1171-1179. doi:10.19982/j.issn.1000-6621.20250152. |
| [14] | World Health Organization. Tuberculosis patient cost surveys: a handbook[R]. Geneva: World Health Organization, 2017. |
| [15] | 马晓雪, 黄爱菊, 陈慧娟, 等. 毕节市敏感肺结核患者家庭灾难性支出情况分析[J]. 现代预防医学, 2022, 49(3): 527-531. doi:10.3969/j.issn.1003-8507.2022.3.xdyfyx202203029. |
| [16] | 梁祖花, 潘春柳, 汪俊华, 等. 2021-2022年贵州省贵阳市肺结核患者灾难性支出及影响因素研究[J]. 疾病监测, 2024, 39(5): 647-654. doi:10.3784/jbjc.202309180461. |
| [17] | Ma X, Huang A, Chen H, et al. Household economic burden and catastrophic expenditures in non-resistant tuberculosis patients: cross-sectional survey in guizhou, china[J]. Front Public Health, 2025, 13: 1510195. doi:10.3389/fpubh.2025.1510195. |
| [18] | 黄爱菊, 马晓雪, 陈慧娟, 等. 2020年贵州省少数民族普通肺结核患者家庭灾难性支出情况及影响因素分析[J]. 疾病监测, 2024, 39(11): 1502-1508. doi:10.3784/jbjc.202404240263. |
| [19] |
Zhou C, Long Q, Chen J, et al. Factors that determine catastrophic expenditure for tuberculosis care: a patient survey in China[J]. Infect Dis Poverty, 2016, 5: 6. doi:10.1186/s40249-016-0100-6.
pmid: 26806552 |
| [20] | Zhang T, Tang S, Jun G, et al. Persistent problems of access to appropriate, affordable TB services in rural China: experiences of different socio-economic groups[J]. BMC Public Health, 2007, 7(19): 19. doi:10.1186/1471-2458-7-19. |
| [21] | Meghji J, Gregorius S, Madan J, et al. The long term effect of pulmonary tuberculosis on income and employment in a low income, urban setting[J]. Thorax, 2021, 76(4): 387-395. doi:10.1136/thoraxjnl-2020-215338. |
| [22] | Xu K, Evans D B, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis[J]. The Lancet, 2003, 362(9378): 111-117. doi:10.1016/S0140-6736(03)13861-5. |
| [23] | 丁丞, 嵇仲康, 郑琳, 等. 人群主动筛查策略助力结核病防控[J]. 浙江大学学报(医学版), 2022, 51(6): 669-678. doi:10.3724/zdxbyxb-2022-0426. |
| [1] | Xu Yong, Zhou Teng, Liu Junjia. Construction and validation of a risk prediction model for restenosis after interventional treatment of tuberculous airway stenosis [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 760-768. |
| [2] | Li Qin, Li Linhong, Liu Jiao, Feng Mei, Xie Qi, Zhang Guixian, Yang Qiong, Yang Dandan. A case of AIDS with rifampicin-resistant tuberculous breast abscess and literature review [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 687-693. |
| [3] | Su Wei, Bai Xinyu, Maiwulajiang Yimamu, Keyoumu Wubulikasimu, Diermulati Tusun, Lai Fuli, Mirenisha Abudurexiti, Xirizhati Mamuti, Zhou Linjun, Huang Fei. Survival status and influencing factors analysis of patients with rifampicin-resistant pulmonary tuberculosis in Kashgar Prefecture, Xinjiang Uygur Autonomous Region, 2013—2022 [J]. Chinese Journal of Antituberculosis, 2026, 48(2): 197-205. |
| [4] | Nie Wenjuan, Zhang Mingyue, Zhang Yungui, Rukeyamu·Abudushalamu , Xu Bing, Jin Long, Liang Ruixia, Wang Furong, Xiong Yu, Cui Junwei, Yi Hengzhong, Zhang Fan, Li Hongzhi, Cao Xuegang, Qiu Lei, Bao Zhijian, Wang Guangming, Zhang Fan, Song Yanan, Zhang Haiqin, Chu Naihui, Cheng Shiming. A 6-month short-course regimen for rifampicin-resistant pulmonary tuberculosis in China: a nationwide multicenter single-arm clinical trial [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1480-1486. |
| [5] | Li Rong, Wang Hua, Zhang Xuejue, Jin Long, Rukeyamu Abudushalamu, Jin Xiuye, Jing Yangfei, Yang Hong, Wu Yanqin, Ren Fei, Nie Wenjuan. Research on the safety of the B-Pa-L/M regimen in the treatment of rifampicin-resistant pulmonary tuberculosis in elderly patients (≥65 Years) [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1515-1522. |
| [6] | Zhang Yaning, Yang Peirong, Yan Chuanyuan, Li Hongbing, Xiao Yuyu, Zhang Lu. Construction and validation of a prediction model for pulmonary tuberculosis-affected households facing catastrophic costs in Baoji City [J]. Chinese Journal of Antituberculosis, 2025, 47(9): 1171-1179. |
| [7] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
| [8] | Liu Ling, Zeng Yi, Wang Jin, Liu Xiaoling, Liu Yan, Lin Feishen, Guo Jing. Construction and evaluation of a model for predicting malnutrition in patients with pulmonary tuberculosis and diabetes mellitus [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 903-909. |
| [9] | Zhang Hongtai, Ren Yixuan, Hu peilei, Wang Nenhan, Li Jie, Tian Lili, Zhao Yanfeng, Chen Shuangshuang, Li Chuanyou. Comparison of microbiota diversity in the sputum of pulmonary tuberculosis patients with rifampicin resistance or sensitivity [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 625-633. |
| [10] | Geng Junling, Zhang Yinan, Pan Hongqiu. Establishment and validation of a risk prediction model for drug-induced liver injury in patients with tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 699-706. |
| [11] | Gulina Badeerhan, Liu Nianqiang, Yipaer Aihaiti, Wang Le, Wang Senlu, Zulikatiayi Abudula, Wang Mingzhe, Zhang Jing, Wang Xinqi, Bi Hongbo. The effect of GeneXpert MTB/RIF detection technology in tuberculosis prevention and control program in Xinjiang [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 173-177. |
| [12] | Ruan Yunzhou, Su Wei, Zhang Hui, Zhao Yanlin. Historical evolution and prospect of rifampicin-resistant tuberculosis prevention and control in China [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1166-1170. |
| [13] | Li Jing, Jiang Qi, Jiang Yuan, Shen Xin. Evaluation of performance of PCR fluorescent probe method for detecting Mycobacterium tuberculosis complex and rifampicin resistance [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1250-1258. |
| [14] | Liu Mei, Wu Xia, Gu Xu, Li Nana, Zhang Wanmin, Zhang Xiaoke, Lan Yuanbo. Evaluation of the performance of InnowaveDX MTB/RIF in detecting Mycobacterium tuberculosis complex and rifampicin resistance [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 70-74. |
| [15] | Lyu Tong, Yang Yunbin, Pan Ying, Cheng Yuyu, Li Zichao, Xu Lin. Analysis of economic burden and influencing factors of rifampin-resistant pulmonary tuberculosis in Yunnan Province [J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1031-1037. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.